ORYZON to give updates on corporate progress in November

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in November.

Oryzon’s medical team will participate at the Kabuki Syndrome Foundation Annual Conference, which will be held virtually on November 4. The company will present two brief oral communications about epigenetic medicines for genetic syndromes and the upcoming vafidemstat's Phase I/II HOPE trial in Kabuki syndrome to an audience of KS investigators and KS patients and families”. Click on link for more info about the Kabuki Syndrome Foundation 2022 Conference.

Oryzon will participate at the 11th Drug Discovery Strategic Summit 2022, which will be held in Amsterdam (Netherlands) on November 10-11, where the company will present an oral communication entitled: “Target validation adventures: HDAC6 as an example”. Click on link for more info about the 11th Drug Discovery Strategic Summit.

Oryzon will participate at the Inv€$tival Showcase LSX Leaders 2022 conference, which will be held on November 14 in London (United Kingdom). The company will take part in a panel entitled “CNS and the Market -- What is New in the Pipeline and in Deal Activity?”on November 14 at 15:00 local time. Click on link for more info about the Inv€$tival Showcase LSX Leaders conference.

Oryzon will also attend the annual Jefferies London Healthcare Conference 2022, which will be held in London (United Kingdom) on November 15-17, where the company will provide a corporate update and will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about Jefferies Healthcare Conference 2022.